GSK/Adolor’s Entereg Gets Nov. 9 User Fee Date
This article was originally published in The Pink Sheet Daily
Executive Summary
Adolor is also pursuing almivopan/opioid analgesic combination product for postoperative ileus.
You may also be interested in...
Entereg Fails Phase III Trial; Adolor/GSK To Re-Examine Placebo Effect
Disappointing results throw into question the timing of sNDA submission.
Entereg Fails Phase III Trial; Adolor/GSK To Re-Examine Placebo Effect
Disappointing results throw into question the timing of sNDA submission.
Adolor's Entereg "Approvable"; Ongoing Study May Provide Confirmatory Data
FDA is requesting that the company confirm efficacy of the postoperative ileus therapy. An ongoing Phase III trial with Entereg could address FDA's concerns.